Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma

Cancer Science

Volumn 97, Issue 9, 2006, Pages 933-937

  Niitsu, Nozomi ^a   Kohuri, Mika ^a   Higashihara, Masaaki ^b   Bessho, Masami ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; BRAIN NATRIURETIC PEPTIDE; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; MITOXANTRONE; NUCLEOSIDE DIPHOSPHATE KINASE A; PREDNISONE; RITUXIMAB; TROPONIN T; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LARGE CELL LYMPHOMA; LIVER TOXICITY; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RIGOR; SURVIVAL RATE; THROMBOCYTOPENIA;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MITOXANTRONE; NATRIURETIC PEPTIDE, BRAIN; NUCLEOSIDE-DIPHOSPHATE KINASE; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; TROPONIN T; TUMOR MARKERS, BIOLOGICAL;

EID: 33746591730     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00249.x     Document Type: Article

References (20)

1. Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-26.
2. Pommier Y. DNA topoisomerase I and II in cancer chemotherapy: Update and perspectives. Cancer Chemother Pharmacol 1993; 32: 103-8.
3. Ohno R, Yoshida Y, Oguro M et al. An early phase II study of CPT-11 (Irinotecan hydrochloride) in patients with hematological malignancies. Jpn J Cancer Chemother 1994; 21: 75-82.
4. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992; 50: 604-10.
5. Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T, Okada K. Experiment studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 1992; 50: 760-6.
6. Ohtsu T, Sasaki Y, Igarashi T, Murayama T, Kobayashi Y, Tobinai K. Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide. Jpn J Clin Oncol 1998; 28: 502-6.
7. Coltman CA Jr, Coltman TM, Balcerzak SP, Morrison FS, Von Hoff DD. Mitoxantrone in refractory nonHodgkin's lymphoma. A Southwest Oncology Group study. Semin Oncol 1984; 11: 50-3.
8. Niitsu N, Iijima K, Chizuka A. Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: A pilot study. Ann Hematol 2001; 7: 411-6.
9. Niitsu N, Okabe-Kado J, Okamoto M et al. Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin's lymphoma. Blood 2001; 97: 1202-10.
10. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). WHO Health Organazation Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001.
11. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1.
12. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-53.
13. Niitsu N, Okabe-Kado J, Kasukabe T, Yamamoto-Yamaguchi Y, Umeda M, Honma Y. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma. Blood 1999; 94: 3541-50.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
15. Sarris AH, Phan A, Goy A et al. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial. Oncology 2002; 16: 27-31.
16. Ribrag V, Koscielny S, Vantelon JM et al. Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas. Leuk Lymphoma 2003; 44: 1529-33.
17. Sugiyama K, Omachi K, Fujiwara K et al. Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: A single institution experience. Cancer 2002; 94: 594-600.
18. Tobinai K, Hotta T, Saito H et al. Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. CPT-11/Lymphoma Study Group. Jpn J Clin Oncol 1996; 26: 455-60.
19. Suzumiya J, Suzushima H, Maeda K et al. Kyushu Hematology Organization for Treatment Study Group. Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma. Int J Hematol 2004; 79: 266-70.
20. Steeg PS, Bevilacqua G, Kopper L et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988; 80: 200-4.